<DOC>
	<DOC>NCT00378066</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.</brief_summary>
	<brief_title>Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically or cytologically documented colorectal adenocarcinoma ECOG performance status of 2 or lower Adequate bone marrow function Adequate kidney function Adequate liver function Informed consent Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start Known allergy to study drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>